Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 7/20 | 0.40 |
| ▸ | NOS3 | P29474 | 6/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | BRS3 | P32247 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702538 | 0.79 | NOS1 (0.49) | ASIC3NOS1NOS3P2RY14CHRM2 | |
| SCHEMBL6703459 | 0.78 | P2RY14 (0.35) | ASIC3P2RY14TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL6703457 | 0.77 | RARG (0.38) | P2RY14TMEM97SIGMAR1ALDH1A1POLB | |
| SCHEMBL6701030 | 0.77 | NOS1 (0.53) | ASIC3NOS1NOS3P2RY14CHRM2 | |
| SCHEMBL6700994 | 0.73 | NOS1 (0.36) | ASIC3NOS1NOS3P2RY14SIGMAR1 | |
| SCHEMBL10007713 | 0.71 | GAA (0.40) | P2RY14TMEM97SIGMAR1 | |
| SCHEMBL7086968 | 0.71 | ASIC3 (0.32) | ASIC3 | |
| SCHEMBL6757805 | 0.70 | CHRNB2 (0.37) | P2RY14TMEM97SIGMAR1ALDH1A1CHRM2 | |
| SCHEMBL6695621 | 0.68 | ASIC3 (0.50) | ASIC3NOS1NOS3SIGMAR1PDPK1 | |
| SCHEMBL8082146 | 0.66 | MAPT (0.72) | ASIC3NOS1NOS3PDPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER INC | 2004-07-22 | — | — | US | disclosed |
| EP-0946512-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-03-14 | — | — | US | disclosed |
| US-6235750-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | ASIC3 3793/4885NOS1 1/4885NOS3 3/4885 |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | ASIC3 3793/4885NOS1 1/4885NOS3 3/4885 |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | ASIC3 3793/4885NOS1 1/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.